Table 5 The association between IFN-γ and sustained virologic response in HCV subgroups (HCV genotype 1b vs. non-1b).

From: Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C

IFN-γ (pg/ml)

HCV genotype Non-1b

HCV genotype 1b

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

(n = 40)

(n = 8)

p-value

OR (95% C.I)

(n = 33)

(n = 11)

p-value

OR (95% C.I)

IFN-γ 4wk

 <180

32 (88.9%)

4 (11.1%)

0.094

1.33 (0.88~2.02)

32 (84.2%)

6 (15.8%)

0.002

5.05 (0.84~30.40)

 ≧180

8 (66.7%)

4 (33.3%)

  

1 (16.7%)

5 (83.3%)

  

IFN-γ 12wk

 <120

29 (93.5%)

2 (6.5%)

0.017

1.45 (1.01~2.08)

24 (85.7%)

4 (14.3%)

0.067

1.54 (0.96~2.41)

 ≧120

11 (64.7%)

6 (35.3%)

  

9 (56.3%)

7 (43.7%)

  

IFN-γ EOT

 <40

28(90.3%)

3(9.7%)

0.112

1.28 (0.92~1.78)

24 (88.9%)

3 (11.1%)

0.012

1.68 (1.05~2.68)

 ≧40

12(70.6%)

5(29.4%)

  

9 (52.9%)

8 (47.1%)

  
  1. p.s. EOT: end of treatment.
Back to article page